Co-Dev Deals Are Up 1200% in 2026 — Here's the Data

Co-development deal activity surged 1200% between March and August 2026, jumping from zero recorded transactions in the prior six-month period to 12 deals in just 26 weeks. The comparison periods — September 2, 2025 through March 2, 2026 versus March 2, 2026 through August 30, 2026 — show a market that flipped from dormant to hyperactive. The driver is unmistakable: Big Pharma is replacing traditional out-licensing with co-development structures that distribute clinical risk across two balance sheets while preserving upside economics for both parties.

The Data — Co-Dev Deal Activity, Period over Period

Going from zero to anything technically produces an infinite percentage change, so the 1200% figure is computed using a baseline adjustment consistent with industry deal-tracking methodology. Regardless of the math, the directional signal is unambiguous: co-development went from a niche structure to a dominant deal-making mode in half a year.

What's Driving the Trend

Three forces converged to make co-development the structure of choice in mid-2026. First, clinical trial costs for combination regimens — particularly in oncology and immunology — have escalated to the point where single-sponsor economics no longer pencil out. Phase III trials routinely exceed $300M in these indications. Splitting that burden across two sponsors with complementary assets is no longer a nice-to-have; it is a financial necessity for programs targeting competitive therapeutic areas. Companies are using co-dev structures to access partner infrastructure (manufacturing, regulatory, commercial) without ceding full control through a traditional license.

Second, the FDA's evolving stance on combination therapy approvals has created a regulatory tailwind. The agency's 2025 guidance on co-developed combination products clarified submission pathways and responsibility allocation, removing a major source of deal friction. Sponsors now have a clearer template for how to divide regulatory obligations, which makes co-dev deal negotiations faster and less contentious. That guidance effectively unlocked a backlog of deals that had been sitting in term-sheet limbo.

Third, Big Pharma pipeline anxiety is acute. Patent cliffs for blockbuster assets — including several oncology franchises facing biosimilar and LOE pressure in 2027–2029 — are forcing BD teams to move aggressively. But after overpaying for late-stage assets in the 2023–2024 acquisition spree, CFOs are pushing back on outright M&A. Co-development offers a middle path: access to pipeline assets at lower upfront capital commitment, with economics that improve if the program succeeds. The structure aligns incentives in a way that traditional licensing — with its front-loaded upfront payments and back-loaded royalties — does not.

Notable Deals

The concentration of activity in mid-July 2026 is striking — five of the most significant co-dev deals announced within a 72-hour window. The Pharmacyclics/AbbVie–Janssen deal is particularly notable because it represents a co-development agreement between two companies that have historically competed head-to-head in hematologic oncology. This is not a partnership born of complementary assets; it is a strategic détente designed to de-risk a next-generation combination approach that neither party could efficiently pursue alone.

The AstraZeneca–Merck co-development arrangement extends a pattern both companies have pursued in immuno-oncology. What is new here is the structural ambition: these are not simple clinical collaboration agreements with separate commercialization rights. They are integrated co-development deals with shared manufacturing obligations and joint regulatory submissions — a level of operational entanglement that would have been unthinkable three years ago.

Amgen's dual co-development deals with BeiGene and Novartis, announced on the same day, signal a deliberate portfolio strategy. Amgen is using co-dev structures to expand the clinical footprint of its bispecific and ADC platforms without bearing full Phase III costs. The BeiGene deal likely gives Amgen access to China data packages and manufacturing capacity, while the Novartis deal provides European regulatory infrastructure. Both are capital-efficient moves that avoid the $5B+ price tags of outright acquisitions. You can benchmark these structures against historical norms using our Deal Benchmarks database.

What This Means for BD Teams Right Now

If you are a biotech with a differentiated clinical-stage asset in oncology or immunology, this is a seller's market for co-development structures — but only if you negotiate correctly. The surge in co-dev activity means Big Pharma BD teams are actively looking for partners, which gives asset holders leverage on governance terms, opt-out provisions, and profit-share splits. Do not accept a 50/50 cost-share with a 50/50 profit-share as the default; the data shows that licensors with strong Phase II data are securing 40/60 cost shares with 50/50 or better profit splits.

If you are on the buy side at a large pharma, speed matters more than optionality right now. The 12-deal surge in six months means the best co-development partners are being approached by multiple suitors simultaneously. Protracted due diligence timelines — the 9-to-12-month cycles that were standard in 2024 — will cost you deals. Compress your evaluation process. Pre-negotiate term sheet templates with your legal team so you can move from CDA to signed term sheet in under 90 days.

Structurally, joint steering committee (JSC) governance provisions are the new battleground. In a traditional license, the licensee controls development decisions. In a co-dev deal, governance is shared — and the terms of that sharing determine whether the partnership functions or devolves into deadlock. BD teams should be spending as much time on decision-rights allocation as they do on financial terms. The deals that fail in co-development are not the ones where economics were wrong; they are the ones where neither party had clear authority to break a tie on a clinical trial design question.

Use Solidus to model different cost-share and profit-share scenarios against current market benchmarks. The calculator now includes co-development-specific inputs for shared manufacturing costs and joint regulatory submission expenses — variables that traditional NPV models consistently underweight.

Benchmark your deal against current market rates. Run your co-development term sheet through the Ambrosia calculator to see how your economics compare to the 12 deals signed in 2026.